1051375-10-0
Chemical Structure
Cabotegravir
Synonym(s): GSK-1265744; S/GSK1265744
- CAS No.: 1051375-10-0
- Formula:C19H17F2N3O5
- Molecular Weight:405.35
IUPAC Name: (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
InChIKey: WCWSTNLSLKSJPK-LKFCYVNXSA-N
SMILES: FC1=C(CNC(C2=CN3C(C(N([C@@H](C)CO4)[C@@]4([H])C3)=O)=C(O)C2=O)=O)C=CC(F)=C1
Biological Activity: Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cabotegravir | 99.92% | Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabotegravir (Standard) | ≥98% | Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabotegravir-d3-1 | Cabotegravir d3-1 (GSK-1265744-d3-1) is a deuterium substitute of Cabotegravir. Cabotegravir is a potent HIV integrase inhibitor used in AIDS research | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabotegravir-d5 | 99.31% | Cabotegravir-d5 is deuterium labeled Cabotegravir. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cabotegravir-d6 | Cabotegravir-d6 (GSK-1265744-d6) is the deuterium labeled Cabotegravir (HY-15592). Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhou T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018 Jan;151:53-65. [Content Brief]
- [2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [Content Brief]
